Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025
Edgewise Therapeutics (Nasdaq: EWTX), a muscle disease biopharmaceutical company, has announced its upcoming participation at the Leerink Partners Global Healthcare Conference. The presentation is scheduled for Tuesday, March 11, 2025, at 1:40 pm ET.
The event will feature a live webcast accessible through the Edgewise Events & Presentations page. Viewers are advised to connect several minutes before the start time to ensure proper connection. The presentation recording will be available for -time replay after the conference.
Edgewise Therapeutics (Nasdaq: EWTX), un'azienda biofarmaceutica specializzata nelle malattie muscolari, ha annunciato la sua prossima partecipazione alla Conferenza Globale sulla Sanità di Leerink Partners. La presentazione è programmata per martedì 11 marzo 2025, alle 13:40 ET.
L'evento includerà una trasmissione in diretta accessibile attraverso la pagina Eventi e Presentazioni di Edgewise. Si consiglia agli spettatori di collegarsi alcuni minuti prima dell'orario di inizio per garantire una connessione adeguata. La registrazione della presentazione sarà disponibile per la visione successiva dopo la conferenza.
Edgewise Therapeutics (Nasdaq: EWTX), una empresa biofarmacéutica dedicada a las enfermedades musculares, ha anunciado su próxima participación en la Conferencia Global de Salud de Leerink Partners. La presentación está programada para el martes 11 de marzo de 2025, a la 1:40 p. m. ET.
El evento contará con una transmisión en vivo accesible a través de la página de Eventos y Presentaciones de Edgewise. Se aconseja a los espectadores que se conecten varios minutos antes de la hora de inicio para asegurar una conexión adecuada. La grabación de la presentación estará disponible para su reproducción posterior después de la conferencia.
Edgewise Therapeutics (Nasdaq: EWTX), 근육 질환 생명공학 회사,가 Leerink Partners 글로벌 헬스케어 컨퍼런스에 참여할 예정이라고 발표했습니다. 발표는 2025년 3월 11일 화요일, 오후 1시 40분 ET에 예정되어 있습니다.
이 행사는 Edgewise 이벤트 및 발표 페이지를 통해 접근할 수 있는 실시간 웹캐스트를 포함합니다. 시청자는 시작 시간 몇 분 전에 연결하여 적절한 연결을 보장하는 것이 좋습니다. 발표 녹화는 컨퍼런스 후 재생을 위해 제공될 것입니다.
Edgewise Therapeutics (Nasdaq: EWTX), une entreprise biopharmaceutique spécialisée dans les maladies musculaires, a annoncé sa prochaine participation à la Conférence Mondiale sur la Santé de Leerink Partners. La présentation est prévue pour mardi 11 mars 2025, à 13h40 ET.
L'événement comprendra un webinaire en direct accessible via la page Événements et Présentations d'Edgewise. Les spectateurs sont invités à se connecter plusieurs minutes avant l'heure de début pour garantir une connexion adéquate. L'enregistrement de la présentation sera disponible pour une rediffusion après la conférence.
Edgewise Therapeutics (Nasdaq: EWTX), ein biopharmazeutisches Unternehmen für Muskelerkrankungen, hat seine bevorstehende Teilnahme an der Leerink Partners Global Healthcare Conference bekannt gegeben. Die Präsentation ist für Dienstag, den 11. März 2025, um 13:40 Uhr ET geplant.
Die Veranstaltung wird einen Live-Webcast bieten, der über die Seite Veranstaltungen & Präsentationen von Edgewise zugänglich ist. Den Zuschauern wird geraten, sich einige Minuten vor Beginn der Veranstaltung zu verbinden, um eine ordnungsgemäße Verbindung sicherzustellen. Die Aufzeichnung der Präsentation wird nach der Konferenz für eine spätere Wiedergabe verfügbar sein.
- None.
- None.
The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X , Facebook and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250304316655/en/
Edgewise Contacts
Investors:
Michael Carruthers, Chief Financial Officer
ir@edgewisetx.com
Media:
Maureen Franco, VP Corporate Communications
media@edgewisetx.com
Source: Edgewise Therapeutics
FAQ
When is Edgewise Therapeutics (EWTX) presenting at the Leerink Partners Conference?
How can investors watch the EWTX Leerink Conference presentation?
What type of company is EWTX stock?
Will the EWTX Leerink presentation be available for replay?
